Continue to learn
On November 10, 2024, the kick-off meeting of the Phase I/II clinical trial of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) independently developed by Maxvax was held in China’s Henan Province, and the enrollment of the first subjects was completed on the same day, marking the official start of the clinical trial of this vaccine candidate.
more >On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE).
more >On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration （Acceptance No.: CXSL2400228）.
more >Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >
On November 10, 2024, the kick-off meeting of the Phase I/II clinical trial of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) independently developed by Maxvax was held in China’s Henan Province, and the enrollment of the first subjects was completed on the same day, marking the official start of the clinical trial of this vaccine candidate.
more >
On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >
Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >
On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE).
more >
On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration （Acceptance No.: CXSL2400228）.
more >
Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >